TNF-blocking therapy in rheumatoid arthritis and ankylosing spondylitis: why is cost-effectiveness a major issue?

Current rheumatology reports

Volumn 7, Issue 4, 2005, Pages 254-258

  Merkesdal, Sonja ^a   Zeidler, Henning ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; COST BENEFIT ANALYSIS; DRUG ANTAGONISM; DRUG COST; ECONOMICS; HUMAN; IMMUNOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27244442955     PISSN: 15233774     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11926-005-0032-9     Document Type: Review

References (20)